Sirtuin 2抑制通过全基因组染色质重塑诱导ATRX缺陷恶性胶质瘤衰老
本研究利用多组学与Broad Institute Connectivity Map筛选可逆转ATRX缺陷转录改变的药物,发现III类HDAC Sirtuin2(SIRT2)是ATRX缺陷细胞表型的核心介质及不良预后驱动因素;SIRT2抑制可逆转Atrx缺陷转录特征、损害迁移、增加衰老标志物表达,并在体内抑制ATRX缺陷胶质瘤干细胞生长、增加衰老,伴随全基因组增强子相关H3K27ac和H4K16ac标记变化,KLF16为表型逆转介质。
要点
- SIRT2是ATRX缺陷胶质瘤细胞表型的核心介质和不良预后驱动因素。
- SIRT2抑制逆转Atrx缺陷转录特征,损害迁移,增加衰老标志物表达。
- SIRT2抑制在体内抑制ATRX缺陷胶质瘤干细胞生长并增加衰老。
核心结论
- SIRT2抑制通过全基因组染色质重塑选择性靶向ATRX缺陷胶质瘤以诱导衰老,并广泛展示了对抗癌症复杂表观遗传重编程的可行方法。
研究设计与样本
- 利用整合多组学和Broad Institute Connectivity Map(CMAP)鉴定可逆转ATRX缺陷转录改变的候选药物,并采用疾病相关实验模型评估功能表型,结合表观基因组分析阐明分子机制。
主要发现
- CMAP分析及转录/表观基因组分析提示III类HDAC Sirtuin2(SIRT2)是ATRX缺陷细胞表型的中心介质和ATRX缺陷胶质瘤不良预后的驱动因素。
- SIRT2抑制剂逆转小鼠神经上皮祖细胞(mNPCs)中Atrx缺陷转录特征,损害Atrx/ATRX缺陷mNPCs和人胶质瘤干细胞(GSCs)的细胞迁移,并增加胶质瘤模型中衰老标志物表达。
- SIRT2抑制在体内损害ATRX缺陷GSCs生长并增加衰老。
- 上述效应伴随全基因组增强子相关H3K27ac和H4K16ac标记变化,其中H4K16ac与SIRT2依赖性表型逆转显示引人注目的转录联系。
- 基序分析鉴定转录因子KLF16为SIRT2抑制后Atrx缺陷细胞表型逆转的介质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Functional inactivation of ATRX characterizes large subgroups of malignant gliomas in adults and children. ATRX deficiency in glioma induces widespread chromatin remodeling, driving transcriptional shifts and oncogenic phenotypes. Effective strategies to therapeutically target these broad epigenomic sequelae remain undeveloped. METHODS: We utilized integrated multiomics and the Broad Institute Connectivity Map (CMAP) to identify drug candidates that could potentially revert ATRX-deficient transcriptional changes. We then employed disease-relevant experimental models to evaluate functional phenotypes, coupling these studies with epigenomic profiling to elucidate molecular mechanism(s). RESULTS: CMAP analysis and transcriptional/epigenomic profiling implicated the Class III HDAC Sirtuin2 (SIRT2) as a central mediator of ATRX-deficient cellular phenotypes and a driver of unfavorable prognosis in ATRX-deficient glioma. SIRT2 inhibitors reverted Atrx-deficient transcriptional signatures in murine neuroepithelial progenitor cells (mNPCs), impaired cell migration in Atrx/ATRX-deficient mNPCs and human glioma stem cells (GSCs), and increased expression of senescence markers in glioma models. Moreover, SIRT2 inhibition impaired growth and increased senescence in ATRX-deficient GSCs in vivo. These effects were accompanied by genome-wide shifts in enhancer-associated H3K27ac and H4K16ac marks, with the latter in particular demonstrating compelling transcriptional links to SIRT2-dependent phenotypic reversals. Motif analysis of these data identified the transcription factor KLF16 as a mediator of phenotype reversal in Atrx-deficient cells upon SIRT2 inhibition. CONCLUSIONS: Our findings indicate that SIRT2 inhibition selectively targets ATRX-deficient gliomas for senescence through global chromatin remodeling, while demonstrating more broadly a viable approach to combat complex epigenetic rewiring in cancer.
引用
- Malgulwar PB, Danussi C, Dharmaiah S, et al. Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma. Neuro Oncol. 2024. PMID: 37625115. doi:10.1093/neuonc/noad155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。